πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

5,609 results for β€œAB” Clear

  1. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial
  2. CYCLIZINE , CALCIUM CARBONATE , Placebo for azd9550, CALCIUM CITRATE , CALCIUM GLUCONATE , Placebo for azd6234, Placebo for azd9550, AZD6234, GLUCOSE , GLUCAGON , ONDANSETRON

    AstraZeneca AB

    Investigating obesity or overweight condition correlated to many co-morbidities

    phase 2 small molecule active

    1 trial
  3. CYCLOPHOSPHAMIDE , RITUXIMAB , AB-101, FLUDARABINE

    Artiva Biotherapeutics

    Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), SjΓΆgren’s Disease (SjD)

    phase 2 small molecule active

    1 trial
  4. CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial
  5. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial
  6. CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB

    Novartis Pharmaceuticals

    Severe refractory idiopathic inflammatory myopathies (IIM)

    phase 2 small molecule active

    1 trial
  7. CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE

    Celgene Europe Limited

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial
  8. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial
  9. CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial
  10. CYTARABINE , LONCASTUXIMAB TESIRINE, RITUXIMAB, BENDAMUSTINE

    Fondazione Telethon ETS

    Mantle cell lymphoma

    phase 2 small molecule active

    1 trial
  11. CYTARABINE, METHYLPREDNISOLONE, Iclusig 15 mg film-coated tablets, METHOTREXATE, VINCRISTINE, PONATINIB, PREDNISONE

    Fondazione Telethon ETS

    Ph+ Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial
  12. CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial
  13. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para soluciΓ³n para perfusiΓ³n, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial
  14. Cabergoline 1 MG

    Monte Rosa Therapeutics

    Lactation Suppressed

    phase 2 small molecule completed

    1 trial
  15. Cabozantinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial
  16. Cabozantinib

    Takeda

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial
  17. Cabozantinib

    Takeda

    Advanced Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial
  18. Cabozantinib Ipsen 20 mg film-coated tablets

    Disc Medicine

    Renal cell carcinom

    phase 2 small molecule active

    1 trial
  19. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  20. Cadonilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial
  21. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial
  22. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial
  23. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial
  24. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources